JP2023093634A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023093634A5 JP2023093634A5 JP2023069317A JP2023069317A JP2023093634A5 JP 2023093634 A5 JP2023093634 A5 JP 2023093634A5 JP 2023069317 A JP2023069317 A JP 2023069317A JP 2023069317 A JP2023069317 A JP 2023069317A JP 2023093634 A5 JP2023093634 A5 JP 2023093634A5
- Authority
- JP
- Japan
- Prior art keywords
- kda
- seq
- fusion protein
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 13
- 102000037865 fusion proteins Human genes 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 102000001690 Factor VIII Human genes 0.000 claims 6
- 108010054218 Factor VIII Proteins 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 229960000301 factor viii Drugs 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 208000031169 hemorrhagic disease Diseases 0.000 claims 1
- 229920001427 mPEG Polymers 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810481941 | 2018-05-18 | ||
| CN201810481941.X | 2018-05-18 | ||
| JP2020564649A JP2021530437A (ja) | 2018-05-18 | 2019-05-16 | 改良されたｆｖｉｉｉ融合タンパク質及びその応用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564649A Division JP2021530437A (ja) | 2018-05-18 | 2019-05-16 | 改良されたｆｖｉｉｉ融合タンパク質及びその応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023093634A JP2023093634A (ja) | 2023-07-04 |
| JP2023093634A5 true JP2023093634A5 (enExample) | 2023-08-16 |
| JP7492780B2 JP7492780B2 (ja) | 2024-05-30 |
Family
ID=68539524
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564649A Pending JP2021530437A (ja) | 2018-05-18 | 2019-05-16 | 改良されたｆｖｉｉｉ融合タンパク質及びその応用 |
| JP2023069317A Active JP7492780B2 (ja) | 2018-05-18 | 2023-04-20 | 改良されたｆｖｉｉｉ融合タンパク質及びその応用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564649A Pending JP2021530437A (ja) | 2018-05-18 | 2019-05-16 | 改良されたｆｖｉｉｉ融合タンパク質及びその応用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12440572B2 (enExample) |
| EP (1) | EP3816181A4 (enExample) |
| JP (2) | JP2021530437A (enExample) |
| KR (1) | KR102575788B1 (enExample) |
| CN (2) | CN113039200B (enExample) |
| BR (1) | BR112020023168A2 (enExample) |
| MA (1) | MA53020A (enExample) |
| MX (1) | MX2020012103A (enExample) |
| WO (1) | WO2019219049A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4534563A1 (en) | 2022-05-25 | 2025-04-09 | Jiangsu Gensciences Inc. | Fviii fusion protein conjugate having extended half-life and use thereof |
| CN116284411B (zh) * | 2023-02-03 | 2024-02-13 | 北京基科晟斯医药科技有限公司 | 抗培重组人凝血因子VIII-Fc融合蛋白的抗体及其应用 |
| CN116036244B (zh) * | 2023-02-24 | 2023-09-19 | 北京基科晟斯医药科技有限公司 | 培重组人凝血因子VIII-Fc融合蛋白用于治疗含抑制物的血友病A的用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4818679A (en) | 1985-02-19 | 1989-04-04 | The Trustees Of Columbia University In The City Of New York | Method for recovering mutant cells |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| EP1003894A2 (en) * | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentiviral vectors |
| SI1824988T1 (sl) | 2004-11-12 | 2017-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| EP1891231A4 (en) | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US20120121613A1 (en) | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| EP2536754A1 (en) * | 2010-02-16 | 2012-12-26 | Novo Nordisk A/S | Factor viii fusion protein |
| EP2536753B1 (en) | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| HK1198541A1 (en) | 2011-10-18 | 2015-05-15 | Csl Limited | Method for improving the stability of purified factor viii after reconstitution |
| CN103172745A (zh) | 2011-12-21 | 2013-06-26 | 北京韩美药品有限公司 | 包含免疫球蛋白Fc片段的长效人内皮抑素 |
| EA035323B1 (ru) | 2012-01-12 | 2020-05-28 | Биовератив Терапьютикс Инк. | Полипептиды химерного фактора viii и их применение |
| WO2014008480A2 (en) * | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
| CN104519912A (zh) | 2012-08-13 | 2015-04-15 | 诺和诺德A/S（股份有限公司） | 液体因子viii制剂 |
| WO2014100913A1 (en) | 2012-12-24 | 2014-07-03 | Beijing Anxinhuaide Biotech. Co., Ltd | Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| CN103539860B (zh) | 2013-11-01 | 2014-12-03 | 广州优联康医药科技有限公司 | 一种长效重组人促卵泡激素融合蛋白 |
| SG11201805497QA (en) * | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
| JP6877469B2 (ja) | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
-
2019
- 2019-05-16 MA MA053020A patent/MA53020A/fr unknown
- 2019-05-16 CN CN201980033170.0A patent/CN113039200B/zh active Active
- 2019-05-16 EP EP19804136.0A patent/EP3816181A4/en active Pending
- 2019-05-16 WO PCT/CN2019/087156 patent/WO2019219049A1/zh not_active Ceased
- 2019-05-16 KR KR1020207034852A patent/KR102575788B1/ko active Active
- 2019-05-16 US US17/055,403 patent/US12440572B2/en active Active
- 2019-05-16 CN CN202310860049.3A patent/CN117467019A/zh active Pending
- 2019-05-16 JP JP2020564649A patent/JP2021530437A/ja active Pending
- 2019-05-16 MX MX2020012103A patent/MX2020012103A/es unknown
- 2019-05-16 BR BR112020023168-1A patent/BR112020023168A2/pt unknown
-
2023
- 2023-04-20 JP JP2023069317A patent/JP7492780B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023093634A5 (enExample) | ||
| TWI250988B (en) | Thrombopoietic compounds | |
| US6072041A (en) | Fusion proteins for protein delivery | |
| JP3280016B2 (ja) | ポリマーとコロニー刺激因子‐１との接合体 | |
| JP2005525302A5 (enExample) | ||
| JPH10502349A (ja) | インテグリンα▲下４▼β▲下１▼のＶＣＡＭ−１またはフィブロネクチンへの結合を阻害する方法 | |
| JP2011518179A5 (enExample) | ||
| RU2183215C2 (ru) | Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего | |
| JP2010515686A5 (enExample) | ||
| HU230160B1 (hu) | Interleukin-I inhibitort és kontrollált felszabadulású polimerként hialuronant tartalmazó készítmények | |
| JP2019108360A5 (enExample) | ||
| JP2765807B2 (ja) | Ｇ−ｃｓｆ及びｔｎｆ結合タンパク質を含む産生物 | |
| JP2009520758A5 (enExample) | ||
| JP2006523709A5 (enExample) | ||
| JP2014088402A (ja) | Ｃ末端におけるポリペプチドの結合 | |
| JP2003530871A (ja) | インテグリン／接着因子アンタゴニスト | |
| JPWO2021116182A5 (enExample) | ||
| JPH08504210A (ja) | 結合生物活性ペプチドを使用した敗血症性ショックの治療 | |
| JPWO2021092081A5 (enExample) | ||
| JP2008133206A (ja) | 緑膿菌に対して感染防御能を誘導できる医薬組成物 | |
| CA2581110A1 (en) | Peptides and apl-type derivatives of hsp60 and pharmaceutical compositions | |
| US7011968B1 (en) | Fragments of virus protein 2 or 3 of the polyoma virus, used for transporting active ingredients | |
| TW200426155A (en) | Activated polyethylene glycol esters | |
| JPWO2021235553A5 (enExample) | ||
| US9187553B2 (en) | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |